Abstract

Genomic studies have provided insights into molecular subgroups and oncogenic drivers of pediatric brain tumors (PBT) that may lead to novel therapeutic strategies. Participants of the cohort Pediatric Brain Tumor Atlas: CBTTC (CBTTC cohort), were randomly divided into training and validation cohorts. In the training cohort, Kaplan-Meier analysis and univariate Cox regression model were applied to preliminary screening of prognostic genes. The LASSO Cox regression model was implemented to build a multi-gene signature, which was then validated in the validation and CBTTC cohorts through Kaplan-Meier, Cox, and receiver operating characteristic curve (ROC) analyses. Also, gene set enrichment analysis (GSEA) and immune infiltrating analyses were conducted to understand function annotation and the role of the signature in the tumor microenvironment. An eight-gene signature was built, which was examined by Kaplan-Meier analysis, revealing that a significant overall survival difference was seen, either in the training or validation cohorts. The eight-gene signature was further proven to be independent of other clinic-pathologic parameters via the Cox regression analyses. Moreover, ROC analysis demonstrated that this signature owned a better predictive power of PBT prognosis. Furthermore, GSEA and immune infiltrating analyses showed that the signature had close interactions with immune-related pathways and was closely related to CD8 T cells and monocytes in the tumor environment. Identifying the eight-gene signature (CBX7, JADE2, IGF2BP3, OR2W6P, PRAME, TICRR, KIF4A, and PIMREG) could accurately identify patients' prognosis and the signature had close interactions with the immunodominant tumor environment, which may provide insight into personalized prognosis prediction and new therapies for PBT patients.

Highlights

  • Brain tumors are the most common solid tumor in pediatrics, accounting for 23.7% of new cancer diagnoses in children [1], and the second most common pediatric malignancy after leukemia [2,3]

  • Advanced genomic analysis of the entire spectrum of PBT heralds an Prognostic eight-gene signature in pediatric brain tumors era in which this defect can be overcome by new technologies that will help us understand the genome pattern of PBT [10]

  • Genomic studies have provided insights into molecular subgroups and oncogenic PBT drivers that may lead to novel therapeutic strategies [11]

Read more

Summary

Introduction

Brain tumors are the most common solid tumor in pediatrics, accounting for 23.7% of new cancer diagnoses in children [1], and the second most common pediatric malignancy after leukemia [2,3]. The life-saving treatments these children receive may result in impaired brain structure and function, leading to long-term major cognitive deficits [1,4,5,6,7,8]. Current treatment options include surgical resection, cranial radiation, and chemotherapy. The distribution, pathology, molecular characteristics, and treatment strategies for pediatric brain tumors (PBT) have essential differences compared to those of the adult population [9]. The lack of advances in PBT treatment was hindered by our lack of knowledge about the molecular pathogenesis of brain tumors [10]. Advanced genomic analysis of the entire spectrum of PBT heralds an Prognostic eight-gene signature in pediatric brain tumors era in which this defect can be overcome by new technologies that will help us understand the genome pattern of PBT [10]. Genomic studies have provided insights into molecular subgroups and oncogenic PBT drivers that may lead to novel therapeutic strategies [11]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.